TriSalus Life Sciences (NASDAQ:TLSI) Issues Quarterly Earnings Results

Key Points

• TriSalus Life Sciences reported a quarterly loss of ($0.27) EPS, missing the consensus estimate by ($0.05).
• The stock's performance saw a slight increase, trading at $3.65, with a market cap of $138.12 million.
• Insider Richard Marshak sold 6,597 shares of the company, leading to an 8.71% decrease in his ownership stake.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05), Zacks reports. The firm had revenue of $11.21 million for the quarter, compared to analyst estimates of $10.69 million. TriSalus Life Sciences updated its FY 2025 guidance to EPS.

TriSalus Life Sciences Price Performance

TriSalus Life Sciences stock traded up $0.67 during midday trading on Friday, hitting $4.55. 141,396 shares of the stock were exchanged, compared to its average volume of 82,086. The company has a 50 day moving average price of $4.78 and a two-hundred day moving average price of $5.21. The firm has a market cap of $172.17 million, a P/E ratio of -3.86 and a beta of 0.48. TriSalus Life Sciences has a 1 year low of $3.42 and a 1 year high of $6.03.

Insider Buying and Selling at TriSalus Life Sciences

In other TriSalus Life Sciences news, insider Richard Marshak sold 6,597 shares of the business's stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $5.18, for a total transaction of $34,172.46. Following the completion of the transaction, the insider directly owned 69,101 shares of the company's stock, valued at $357,943.18. The trade was a 8.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last ninety days, insiders have sold 16,125 shares of company stock worth $83,528. 27.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of large investors have recently made changes to their positions in TLSI. Nantahala Capital Management LLC bought a new stake in TriSalus Life Sciences in the second quarter worth approximately $10,900,000. Gilder Gagnon Howe & Co. LLC grew its position in TriSalus Life Sciences by 32.1% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company's stock worth $5,957,000 after acquiring an additional 265,618 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of TriSalus Life Sciences by 107.4% during the 2nd quarter. Geode Capital Management LLC now owns 455,051 shares of the company's stock worth $2,480,000 after buying an additional 235,627 shares during the period. Bank of America Corp DE boosted its holdings in shares of TriSalus Life Sciences by 1.8% during the 2nd quarter. Bank of America Corp DE now owns 188,906 shares of the company's stock worth $1,030,000 after buying an additional 3,374 shares during the period. Finally, Bridgeway Capital Management LLC boosted its holdings in shares of TriSalus Life Sciences by 16.0% during the 2nd quarter. Bridgeway Capital Management LLC now owns 75,400 shares of the company's stock worth $411,000 after buying an additional 10,400 shares during the period. Institutional investors and hedge funds own 2.58% of the company's stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.